Aspirin and clopidogrel resistance Possible mechanisms and clinical relevance. Part I: Concept of resistance /
Aspirin and clopidogrel are well established as antiplatelet medication in the treatment of atherothrombotic vascular disease. However, despite treatment, a substantial number of patients experience recurrent ischemic episodes, referred to as aspirin or clopidogrel treatment failure. Various laborat...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
Orvos-Egészségügyi Dolgozók Szakszervezete
2012
|
| Sorozat: | IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE
65 No. 11-12 |
| mtmt: | 2233348 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/9884 |
| Tartalmi kivonat: | Aspirin and clopidogrel are well established as antiplatelet medication in the treatment of atherothrombotic vascular disease. However, despite treatment, a substantial number of patients experience recurrent ischemic episodes, referred to as aspirin or clopidogrel treatment failure. Various laboratory techniques are available with which to evaluate the effectiveness of antiplatelet drugs. Interestingly, the agreement between the results of the different tests may be poor. The term aspirin or clopidogrel resistance denotes those conditions in which an inadequate inhibitory efficacy of the given antiplatelet agent is detected by an in vitro assay of platelet function. It has been estimated that on average some 30% of patients treated with aspirin, and 20% on clopidogrel, do not achieve an appropriate level of efficacy as concerns platelet activity. |
|---|---|
| Terjedelem/Fizikai jellemzők: | 377-385 |
| ISSN: | 0019-1442 |